Premium
MiR‐24‐3p enhances cell growth in hepatocellular carcinoma by targeting metallothionein 1M
Author(s) -
Dong Xiaogang,
Ding Wei,
Ye Jianwei,
Yan Dong,
Xue Feng,
Xu Lin,
Yin Jiwei,
Guo Wenjia
Publication year - 2016
Publication title -
cell biochemistry and function
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.933
H-Index - 61
eISSN - 1099-0844
pISSN - 0263-6484
DOI - 10.1002/cbf.3213
Subject(s) - cancer research , microrna , downregulation and upregulation , cell growth , hepatocellular carcinoma , viability assay , metallothionein , biology , cell , reverse transcription polymerase chain reaction , blot , microbiology and biotechnology , chemistry , gene expression , gene , biochemistry
Dysregulation of microRNAs has been demonstrated to contribute to malignant progression of cancers, including hepatocellular carcinoma (HCC). MiR‐24‐3p was previously reported to be significantly upregulated in HCC. However, the potential role and mechanism of action of miR‐24‐3p in the initiation and progression of HCC remain largely unknown. Quantitative reverse transcription polymerase chain reaction demonstrated that miR‐24‐3p was significantly upregulated in HCC tumor tissues compared with nontumor tissues. The cell viability, colony formation assay, and tumorigenicity assays in nude mice showed that miR‐24‐3p could enhance HCC cell growth in vitro and in vivo. Metallothionein 1M was verified as an miR‐24‐3p target gene by using dual‐luciferase reporter assays, quantitative reverse transcription polymerase chain reaction, and Western blotting, which was involved in miR‐24‐3p regulated HCC cell growth. These results indicated that miR‐24‐3p plays an important role in the initiation and progression of HCC by targeting metallothionein 1M, and the miR‐24‐3p/metallothionein 1M pathway may contribute to the development of novel therapeutic strategies for HCC in the future.